The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial (Q37762959)
Jump to navigation
Jump to search
scientific article published on July 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial |
scientific article published on July 2010 |
Statements
1 reference
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial (English)
1 reference
Martin Sebastian
1 reference
Martin Reck
1 reference
Cornelius F Waller
1 reference
Cornelius Kortsik
1 reference
Norbert Frickhofen
1 reference
Martin Schuler
1 reference
Holger Fritsch
1 reference
Birgit Gaschler-Markefski
1 reference
Gertraud Hanft
1 reference
Gerd Munzert
1 reference
Joachim von Pawel
1 reference
1 July 2010
1 reference
1 reference
5
1 reference
7
1 reference
1060-1067
1 reference
Identifiers
1 reference
1 reference